NEW DELHI — The Union Ministry of Health and Family Welfare has notified key amendments to the Drugs Rules, 1945 via Gazette Notification G.S.R. 756 (E), introducing strict debarment penalties for entities that submit fake or fabricated data during the regulatory approval process.
Under the new provisions, the Licensing Authority—at both the Central and State levels—is empowered to debar non-compliant applicants from submitting further applications for a specified duration. Previously, penalties were largely limited to the rejection of individual applications or the cancellation of existing licenses.
Key Highlights of the Regulatory Amendment
-
Enhanced Deterrence: Applicants filing falsified clinical, quality, or safety data can now face temporal debarment across all categories governed by the Drugs Rules, 1945.
-
Due Process Protections: The amendment mandates the mandatory issuance of a formal show-cause notice prior to initiating punitive debarment, while providing a clear formal appeals mechanism.
-
Focus on Integrity: The measure aims to safeguard public health, align Indian drug regulation with global best practices, and penalize fraudulent practices without disrupting compliant manufacturers and distributors.
The official notification is available via the Government of India’s official e-Gazette portal.
